Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company delivering improved outcomes for patients who struggle to control diabetes and related metabolic conditions with current options. The company's lead candidate, clofutriben, is a once-daily, oral HSD-1 inhibitor in development for the millions of patients with type 2 diabetes and elevated cortisol. HSD-1 inhibition is a novel mechanism that complements existing antidiabetic agents by addressing a cause of disease progression and treatment resistance across a spectrum of metabolic dysfunction. Clofutriben has been associated with improved glycemic control while generally safe and well tolerated in multiple clinical trials without requiring dose titration.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/24/25 | $95,000,000 | Series B |
Forbion Capital Partners OrbiMed Advisors RA Capital Management RiverVest Venture Partners US Venture Partners | undisclosed |
